(Q38783026)

6 September 2017

Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review (English)

1 reference

6 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998595%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

M N Joshi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998595%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

M T P Palomar

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998595%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Y Wu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998595%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

P V Carroll

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998595%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

21 March 2016

1 reference

6 September 2017

Clinical Endocrinology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998595%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998595%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998595%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

331-339

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998595%20AND%20SRC:MED&resulttype=core&format=json

Enhancement of antitumor immunity by CTLA-4 blockade

1 June 2020

cites work

1 reference

Immune checkpoint blockade

21 January 2018

1 reference

The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products f

21 January 2018

1 reference

Endocrine side effects induced by immune checkpoint inhibitors.

21 January 2018

1 reference

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

21 January 2018

1 reference

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

21 January 2018

1 reference

CD28 and CTLA-4 coreceptor expression and signal transduction

21 January 2018

1 reference

PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis

21 January 2018

1 reference

PD-1 is a novel regulator of human B-cell activation

21 January 2018

1 reference

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

21 January 2018

1 reference

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

21 January 2018

1 reference

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates

21 January 2018

1 reference

21 January 2018

Autoimmune hypophysitis.

1 reference

Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses

21 January 2018

1 reference

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

21 January 2018

1 reference

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

21 January 2018

1 reference

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study

21 January 2018

1 reference

Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma

21 January 2018

1 reference

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

21 January 2018

1 reference

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

21 January 2018

1 reference

Bevacizumab plus ipilimumab in patients with metastatic melanoma

21 January 2018

1 reference

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.

21 January 2018

1 reference

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

21 January 2018

1 reference

21 January 2018

1 reference

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

21 January 2018

1 reference

Thyroid dysfunction from antineoplastic agents

21 January 2018

1 reference

Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis

21 January 2018

1 reference

Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report

21 January 2018

1 reference

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy

21 January 2018

1 reference

Thyroid dysfunction as an unintended side effect of anticancer drugs.

21 January 2018

1 reference

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

Ipilimumab-induced autoimmune adrenalitis

21 January 2018

1 reference

Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET/CT.

21 January 2018

1 reference

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

21 January 2018

1 reference

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma

21 January 2018

1 reference

Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series

21 January 2018

1 reference

Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis.

21 January 2018

1 reference

Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab

21 January 2018

1 reference

Ipilimumab in the treatment of metastatic melanoma: management of adverse events.

21 January 2018

1 reference

Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review

21 January 2018

1 reference

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

21 January 2018

1 reference

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

21 January 2018

1 reference

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

Drug-induced graves disease from CTLA-4 receptor suppression

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/CEN.13063

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26998595%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference